Adage Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $27.5M | Sell |
84,390
-197,794
| -70% | -$64.5M | 0.05% | 367 |
|
|
2025
Q1 | $76.2M | Buy |
282,184
+189,128
| +203% | +$51.1M | 0.14% | 145 |
|
|
2024
Q4 | $21.9M | Sell |
93,056
-22,944
| -20% | -$5.4M | 0.04% | 423 |
|
|
2024
Q3 | $31.9M | Sell |
116,000
-138,000
| -54% | -$38M | 0.06% | 323 |
|
|
2024
Q2 | $61.7M | Buy |
+254,000
| New | +$61.7M | 0.11% | 184 |
|
|
2022
Q4 | – | Sell |
-485,000
| Closed | -$97.1M | – | 978 |
|
|
2022
Q3 | $97.1M | Buy |
485,000
+315,000
| +185% | +$63.1M | 0.24% | 100 |
|
|
2022
Q2 | $24.8M | Buy |
170,000
+97,700
| +135% | +$14.2M | 0.06% | 357 |
|
|
2022
Q1 | $11.8M | Sell |
72,300
-60,000
| -45% | -$9.8M | 0.02% | 649 |
|
|
2021
Q4 | $22.4M | Buy |
+132,300
| New | +$22.4M | 0.04% | 422 |
|
|
2018
Q2 | – | Sell |
-240,000
| Closed | -$28.6M | – | 732 |
|
|
2018
Q1 | $28.6M | Sell |
240,000
-50,000
| -17% | -$5.96M | 0.07% | 324 |
|
|
2017
Q4 | $36.8M | Buy |
+290,000
| New | +$36.8M | 0.08% | 281 |
|